*STUDY DESIGN: Multicenter, randomized, double-blind efficacy trial of CYSTARAN in 15 treatment-naïve patients with a baseline CCCS of ≥ 1.25. The primary end point was the estimated proportion of eyes with a CCCS reduction ≥1 relative to baseline (where baseline CCCS was ≥1) anytime during the treatment period and at Months 3, 6, 9, and 12. Slit-lamp photography was used to assess CCCS changes from baseline.1,2
†CCCS = Corneal cystine crystal score, a measure of crystal density assessed using slit-lamp photography. CCCS ranges from 0 units (clear at the center) to 3 units (highest crystal density).